Sitagliptin/pioglitazone (MK-0431C; MK-431C) is a fixed dose combination of sitagliptin, DPP-4 inhibitor, and pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR) agonist. It is intended to substitute sitagliptin or pioglitazone, or to be used as an add-on to metformin, for the treatment of patients with type 2 diabetes who are uncontrolled on metformin in combination with pioglitazone or sitagliptin. In phase III clinical trials, sitagliptin was administered orally at 100mg once daily and pioglitazone was administered orally at 15mg to 45mg once daily.
Leriglitazone is expected to work in patients with ALD by activating receptors called ‘PPAR gamma’, found in the mitochondria, which are components within cells that generate energy. Leriglitazone will improve the ALD pathogenic cascade by improving mitochondrial dysfunction, reducing oxidative stress and neuroinflammation, promoting demyelination and halting axonal degeneration. Hence, leriglitazone is expected to protect cells from damage and slow the progression of the disease. If licensed, leriglitazone would offer the first drug treatment option for adult ALD patients with AMN who currently have no effective therapies available.